Bristol Myers Squibb (BMY) announces positive topline results from phase 3 SCOUT-HCM trials evaluating Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy
Importance
Level 1
#BRISTOL-MYERS SQUIBB CO#BMY.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#BMY#GLOBAL NEWS#US EQUITIES